Css LLC Il Raises Position in Merck & Co., Inc. (NYSE:MRK)

Css LLC Il lifted its position in shares of Merck & Co., Inc. (NYSE:MRK) by 43.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,045 shares of the company’s stock after acquiring an additional 4,840 shares during the quarter. Css LLC Il’s holdings in Merck & Co., Inc. were worth $1,596,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Norges Bank purchased a new position in shares of Merck & Co., Inc. during the 4th quarter worth approximately $3,479,799,000. Bank of New York Mellon Corp grew its holdings in Merck & Co., Inc. by 29.7% during the fourth quarter. Bank of New York Mellon Corp now owns 24,213,537 shares of the company’s stock worth $2,408,763,000 after acquiring an additional 5,550,824 shares during the period. Wellington Management Group LLP raised its position in Merck & Co., Inc. by 6.5% in the fourth quarter. Wellington Management Group LLP now owns 80,742,030 shares of the company’s stock worth $8,032,217,000 after acquiring an additional 4,932,647 shares in the last quarter. Northern Trust Corp lifted its holdings in Merck & Co., Inc. by 16.8% in the fourth quarter. Northern Trust Corp now owns 31,377,107 shares of the company’s stock valued at $3,121,395,000 after acquiring an additional 4,511,742 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in shares of Merck & Co., Inc. by 63.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 11,577,535 shares of the company’s stock worth $1,151,642,000 after purchasing an additional 4,480,007 shares in the last quarter. 76.07% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Merck & Co., Inc.

In related news, SVP Dalton E. Smart III sold 4,262 shares of the company’s stock in a transaction that occurred on Friday, April 25th. The shares were sold at an average price of $82.76, for a total transaction of $352,723.12. Following the completion of the transaction, the senior vice president now owns 7,778 shares of the company’s stock, valued at approximately $643,707.28. This represents a 35.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on MRK shares. Guggenheim reiterated a “buy” rating and issued a $115.00 price target on shares of Merck & Co., Inc. in a report on Thursday, April 17th. Morgan Stanley dropped their target price on shares of Merck & Co., Inc. from $113.00 to $106.00 and set an “equal weight” rating for the company in a report on Wednesday, February 5th. Cantor Fitzgerald lowered Merck & Co., Inc. from an “overweight” rating to a “cautious” rating in a research note on Tuesday. StockNews.com cut Merck & Co., Inc. from a “strong-buy” rating to a “buy” rating in a report on Friday, April 25th. Finally, Deutsche Bank Aktiengesellschaft cut Merck & Co., Inc. from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $128.00 to $105.00 in a report on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, twelve have given a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $109.19.

Merck & Co., Inc. Stock Performance

Shares of NYSE MRK opened at $77.92 on Wednesday. The company has a market cap of $195.66 billion, a PE ratio of 11.58, a price-to-earnings-growth ratio of 0.77 and a beta of 0.43. Merck & Co., Inc. has a 12 month low of $73.31 and a 12 month high of $134.63. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.36 and a quick ratio of 1.15. The company has a 50-day simple moving average of $82.80 and a 200-day simple moving average of $91.89.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Thursday, April 24th. The company reported $2.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.16 by $0.06. The firm had revenue of $15.53 billion for the quarter, compared to analyst estimates of $15.59 billion. Merck & Co., Inc. had a net margin of 26.67% and a return on equity of 45.35%. Merck & Co., Inc.’s revenue was down 1.6% compared to the same quarter last year. During the same quarter last year, the business earned $2.07 earnings per share. On average, equities analysts anticipate that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. declared that its Board of Directors has authorized a stock repurchase program on Tuesday, January 28th that permits the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization permits the company to purchase up to 4.1% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s management believes its stock is undervalued.

Merck & Co., Inc. Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.